Chemotherapy Updates

UK SACT Board Consent Forms

Tue, 08 Sep 2026 23:09:20 GMT

Warning in max.default(structure(numeric(0), class = "Date"), na.rm = FALSE):
no non-missing arguments to max; returning -Inf

The standardised UK SACT Consent Forms which are hosted on the CRUK Website have been updated.

According to the CRUK Webpage, the latest updates took place on -Inf and made the following updates:

NHS England updates CDF List

Wed, 05 Aug 2026 23:00:00 GMT

NHS England updates CDF List

NHS England has updated the Cancer Drugs Fund List. The latest version (v1.406) was uploaded to the NHS England Website on Thursday 6, August 2026.

The following changes have been introduced:

Acalabrutinib in combination bendamustine and rituximab (ACA4)

Acalabrutinib in combination with bendamustine and rituximab for UNTREATED mantle cell lymphoma when an autologous stem cell transplant is UNSUITABLE where the following criteria have been met

Recommended for routine commissioning, receiving CDF interim funding

Acalabrutinib in combination with venetoclax (ACA5)

Acalabrutinib in combination with venetoclax for the 1st line treatment of previously untreated chronic lymphocytic leukaemia where the following criteria have been met

Recommended for routine commissioning, receiving CDF interim funding

Gilteritinib (GILT2)

For the treatment of relapsed/refractory FLT3 mutation positive acute myeloid leukaemia in POST PUBESCENT CHILDREN where the following criteria have been met

Medicines For Children form created for TA642

NA (NHSE Policy 2268)

Clinicial Commissioning Policy: added directly into routine commissioning - section B of list

NA (NHSE Policy 2432)

Clinicial Commissioning Policy: added directly into routine commissioning - section B of list

Belantamab mafodotin in combination with bortezomib and dexamethasone (BELA1)

Belantamab mafodotin in combination with bortezomib and dexamethasone as 2nd line treatment of relapsed or refractory myeloma in adult patients where the following criteria have been met

Moved into routine commissioning - section B of list

Encorafenib in combination with binimetinib (ENC3)

For the first line treatment of metastatic BRAF V600 mutation positive non-small cell lung cancer where the following criteria have been met

Moved into routine commissioning - section B of list

Pembrolizumab (PEMB34)

Pembrolizumab for resectable, locally advanced, head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a combined positive score of 1 or more where the following criteria have been met

Moved into routine commissioning - section B of list

Ripretinib (RIP1)

Ripretinib for treating advanced gastrointestinal stromal tumours after 3 more kinase inhibitors where the following criteria have been met

Moved into routine commissioning - section B of list

Vorasidenib (VOR1)

For treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in patients aged 12 years and over where the following criteria have been met

Moved into routine commissioning - section B of list

Zanidatamab (ZANI1)

For the treatment of HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment where the following criteria have been met

Moved into routine commissioning - section B of list

Amivantamab in combination with lazertinib (AMI1)

For the first line treatment of locally advanced or metastatic non-small cell lung cancer in adults whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations where the following criteria have been met

Treatment criterion (#1, 3 and 4) updated

Dostarlimab (DOS1)

Dostarlimab monotherapy for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) recurrent/advanced endometrial carcinoma after prior platinum-based chemotherapy where the following criteria have been met

Treatment criterion (#1, 8, 10 and 11) updated

Inotuzumab ozogamicin (INO2)

The treatment of relapsed/refractory Philadelphia positive and negative B cell precursor acute lymphoblastic leukaemia in CHILD patients where all the following criteria are met:

Treatment criterion (#4, 6, 7 and 10) updated

Isatuximab in combination with pomalidomide and dexamethasone (ISA1)

Isatuximab in combination with pomalidomide and dexamethasone for the 4th line treatment of adult patients with relapsed/refractory multiple myeloma where the following criteria have been met

Treatment criterion (#1, 9 and 14) updated

NA (NIV8)

Treatment criterion (#1 and 5) updated

Nivolumab and ipilimumab (NIV18)

Nivolumab in combination with ipilimumab for treating advanced melanoma

Treatment criterion (#1 and 4) updated

Nivolumab in combination with relatlimab (Opdualag ®) (NIVREL1)

As first immunotherapy for treating unresectable or metastatic melanoma patients aged 12 years or more where the following criteria have been met

Treatment criterion (#1, 5 and 10) updated

Pembrolizumab (PEMB9a)

Pembrolizumab monotherapy for treating unresectable or advanced malignant melanoma (form a): REGISTRATION OF START OF PEMBROLIZUMAB MONOTHERAPY OR OF PREVIOUSLY COMMENCED AND CURRENTLY CONTINUED PEMBROLIZUMAB MONOTHERAPY This form comes in 3 parts. 1. The first part is for patients who are either scheduled to commence pembrolizumab monotherapy or who commenced and continue to receive pembrolizumab monotherapy. 2. The second part of the form which must use the same unique Blueteq identifier is for those benefitting patients who choose to electively discontinue pembrolizumab after 2 or more years of treatment; this second part (patient details be automatically entered) will only appear once the first part of the form is approved and should be completed at the time of elective discontinuation of pembrolizumab. 3. The third part of the form which must use the same unique Blueteq identifier is for those patients registered as having electively and previously stopped pembrolizumab and in whom there is disease progression for which the clinician wishes to re-commence pembrolizumab; this third part of the form (patient details will automatically entered) will only appear once

Treatment criterion (#1 and 5) updated

Pembrolizumab (PEMB16)

For relapsed/refractory classical Hodgkin lymphoma in patients aged 3 years and older who have been treated with stem cell transplantation but never previously received brentuximab vedotin where the following criteria have been met

Treatment criterion (#1, 8, 10 and 11) updated

NHS England updates CDF List

Tue, 30 Jun 2026 23:00:00 GMT

NHS England updates CDF List

NHS England has updated the Cancer Drugs Fund List. The latest version (v1.405) was uploaded to the NHS England Website on Thursday 25, June 2026.

The following changes have been introduced:

Pembrolizumab with chemoradiotherapy (PEMB36)

Pembrolizumab with chemoradiotherapy for untreated locally advanced cervical cancer where the following criteria have been met

Recommended for routine commissioning, receiving CDF interim funding

Daratumumab in combination (with bortezomib, lenalidomide, and dexamethasone) (DAR6)

For UNTREATED multiple myeloma when a stem cell transplant is UNSUITABLE where the following criteria have been met

Date moving into routine commissioning updated

Mirvetuximab soravtansine (MIR1)

For treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer where the following criteria have been met

Date moving into routine commissioning updated

NHS England updates CDF List

Sat, 27 Jun 2026 23:00:00 GMT

NHS England updates CDF List

NHS England has updated the Cancer Drugs Fund List. The latest version (v1.404) was uploaded to the NHS England Website on Tuesday 23, June 2026.

The following changes have been introduced:

Cemiplimab (CEM3)

To treat recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy where the following criteria have been met

Recommended for routine commissioning, receiving CDF interim funding

NA (EPC2)

Moved into routine commissioning - section B of list

Cemiplimab with platinum-based chemotherapy (CEM2)

For untreated advanced non-small-cell lung cancer where the following criteria have been met

Date moving into routine commissioning updated

Serplulimab in combination with carboplatin and etoposide (SER1) ## Serplulimab in combination with carboplatin and etoposide (SER1)

For the first-line treatment of adult patients with extensive-stage small cell lung cancer where the following criteria have been met For the first-line treatment of adult patients with extensive-stage small cell lung cancer where the following criteria have been met

Date moving into routine commissioning updated Treatment criteria (#3) updated

Tisotumab vedotin (TISV1)

For treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment where the following criteria have been met

Date moving into routine commissioning updated

Atezolizumab in combination with carboplatin and etoposide (ATE7)

For the first-line treatment of adult patients with extensive-stage small cell lung cancer where the following criteria have been met

Treatment criterion (#1, 2, 3, 5 and 9) updated; Treatment criterion (#2, 4, 11 and 12) removed

Daratumumab in combination (with bortezomib, lenalidomide, and dexamethasone) (DAR6)

For UNTREATED multiple myeloma when a stem cell transplant is UNSUITABLE where the following criteria have been met

Treatment criteria (#8) updated

Durvalumab in combination with etoposide plus either carboplatin or cisplatin (DUR4)

For the first-line treatment of adult patients with extensive-stage small cell lung cancer where the following criteria have been met

Treatment criterion (#1, 2, 3, 5, 6 and 9) updated; Treatment criterion (#2, 4, 8, 12 and 13) removed

Serplulimab in combination with carboplatin and etoposide (SER1) ## Serplulimab in combination with carboplatin and etoposide (SER1)

Date moving into routine commissioning updated Treatment criteria (#3) updated

Zanidatamab (ZANI1)

For the treatment of HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment where the following criteria have been met

Treatment criteria (#2) corrected

NHS England updates CDF List

Sun, 14 Jun 2026 23:00:00 GMT

NHS England updates CDF List

NHS England has updated the Cancer Drugs Fund List. The latest version (v1.403) was uploaded to the NHS England Website on Monday 8, June 2026.

The following changes have been introduced:

Daratumumab in combination (with bortezomib, lenalidomide, and dexamethasone) (DAR6)

For UNTREATED multiple myeloma when a stem cell transplant is UNSUITABLE where the following criteria have been met

Recommended for routine commissioning, receiving CDF interim funding

NHS England updates CDF List

Thu, 04 Jun 2026 23:00:00 GMT

NHS England updates CDF List

NHS England has updated the Cancer Drugs Fund List. The latest version (v1.402) was uploaded to the NHS England Website on Thursday 4, June 2026.

The following changes have been introduced:

Mirvetuximab soravtansine (MIR1)

For treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer where the following criteria have been met

Recommended for routine commissioning, receiving CDF interim funding

Durvalumab with gemcitabine and cisplatin (DUR8)

For neoadjuvant treatment then alone adjuvant treatment of muscle-invasive bladder cancer where the following criteria have been met

Moved into routine commissioning - section B of list

Durvalumab with chemotherapy (DUR9)

For neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma where the following criteria have been met

Date moving into routine commissioning updated

Lisocabtagene maraleucel (LIS02a)

For treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL) to DLBCL in patients previously treated with two or more lines of systemic therapy where the following criteria have been met This form is for the approval of leucapheresis and manufacture of CAR-T cells. There is a second part to this form which relates to the subsequent infusion of CAR-T cells and this will be available after submission of the first part. The second part of the form (LIS02b) can only be completed as a continuation of this first part of the form (LIS02a) and must be completed on infusion of CAR-T cells otherwise the treating Trust will not be reimbursed for the cost of lisocabtagene maraleucel.

Date moving into routine commissioning updated

NHS England updates CDF List

Thu, 28 May 2026 23:00:00 GMT

NHS England updates CDF List

NHS England has updated the Cancer Drugs Fund List. The latest version (v1.401) was uploaded to the NHS England Website on Friday 29, May 2026.

The following changes have been introduced:

Serplulimab in combination with carboplatin and etoposide (SER1)

For the first-line treatment of adult patients with extensive-stage small cell lung cancer where the following criteria have been met

Recommended for routine commissioning, receiving CDF interim funding

Atezolizumab in combination with nab- paclitaxel (ATE6)

For treating untreated PD-L1-positive, triple negative, unresectable, locally advanced metastatic breast cancer for patients whose tumours express PD-L1 at a level of 1% or more where the following criteria have been met

Treatment criterion (#1 and 12) updated; Treatment criterion (#2 and 13) removed

NA (BRE3)

Indication column updated; Treatment criterion (#1, 5 and 7) updated

NA (BRE5)

Indication column updated; Treatment criterion (#1, 6 and 9) updated

Pertuzumab (PER2a)

Neoadjuvant pertuzumab plus trastuzumab in NODE POSITIVE patients for the neoadjuvant treatment of locally advanced, inflammatory or early breast cancer at high risk of recurrence (PER2a) where the following criteria have been met This form is for patients known to be pathologically node positive prior to commencing neo-adjuvant therapy. On commencing adjuvant treatment with pertuzumab, form PER4a (for node positive patients) must be completed. For patients with locally advanced, inflammatory or early breast cancer who are node negative of unknown nodal status when commencing neo- adjuvant pertuzumab, form PER2b must be used for the neoadjuvant part of treatment followed by form PER4b for the adjuvant part of treatment only if the histology post-surgery is node +ve.

Treatment criterion (#1 and 8) updated

NHS England updates CDF List

Mon, 25 May 2026 23:00:00 GMT

NHS England updates CDF List

NHS England has updated the Cancer Drugs Fund List. The latest version (v1.400) was uploaded to the NHS England Website on Tuesday 26, May 2026.

The following changes have been introduced:

Cemiplimab with platinum-based chemotherapy (CEM2)

For untreated advanced non-small-cell lung cancer where the following criteria have been met

Recommended for routine commissioning, receiving CDF interim funding

NHS England updates CDF List

Wed, 20 May 2026 23:00:00 GMT

NHS England updates CDF List

NHS England has updated the Cancer Drugs Fund List. The latest version (v1.399) was uploaded to the NHS England Website on Thursday 21, May 2026.

The following changes have been introduced:

Tisotumab vedotin (TISV1)

For treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment where the following criteria have been met

Recommended for routine commissioning, receiving CDF interim funding

Durvalumab with chemotherapy (DUR9)

For neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma where the following criteria have been met

Treatment criteria (#4) updated

Pembrolizumab (PEMB8)

Pembrolizumab in combination with pemetrexed- and platinum-based chemotherapy for the first line treatment of PD-L1 positive or negative locally advanced or metastatic non-squamous non-small cell lung cancer where all the following criteria are met:

Treatment criterion (#1 and 6) updated

Pembrolizumab in combination with or nab-paclitaxel (PEMB18)

The treatment of previously untreated locally advanced unresectable or metastatic triple negative breast cancer patients with PD-L1 expression test results of immune cell (IC) <1% and a combined positive score (CPS) of 10 or more where the following criteria have been met

Treatment criterion (#1, 9 and 14) updated; Treatment criterion (#2 and 15) removed

Pembrolizumab monotherapy (PEMB31)

Pembrolizumab MONOTHERAPY for adjuvant treatment after complete tumour resection in adult patients with UICC/AJCC 8th edition stage IIA or IIB or IIIA or N2 only IIIB non-small cell lung cancer and whose disease has not progressed on recently completed adjuvant platinum-based chemotherapy where the following criteria have been met

Treatment criterion (#1, 12 and 16) updated; Treatment criterion (#2, 17 and 18) removed

NHS England updates CDF List

Tue, 19 May 2026 23:00:00 GMT

NHS England updates CDF List

NHS England has updated the Cancer Drugs Fund List. The latest version (v1.398) was uploaded to the NHS England Website on Tuesday 19, May 2026.

The following changes have been introduced:

Lisocabtagene maraleucel (LIS02a)

Recommended for routine commissioning, receiving CDF interim funding

Belantamab mafodotin with pomalidomide and dexamethasone (BELA2)

Belantamab mafodotin with pomalidomide and dexamethasone as 2nd line treatment of relapsed or refractory myeloma in adult patients who previously received lenalidomide as part of 1st line systemic therapy where the following criteria have been met

Moved into routine commissioning - section B of list

NHS England updates CDF List

Thu, 14 May 2026 23:00:00 GMT

NHS England updates CDF List

NHS England has updated the Cancer Drugs Fund List. The latest version (v1.397) was uploaded to the NHS England Website on Thursday 14, May 2026.

The following changes have been introduced:

Durvalumab with chemotherapy (DUR9)

For neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma where the following criteria have been met

Recommended for routine commissioning, receiving CDF interim funding

Niraparib (NIR3)

Moved into routine commissioning - section B of list

Talazoparib plus enzalutamide (TAL2)

For the treatment of metastatic hormone- relapsed (castrate-resistant) prostate cancer in patients who are treatment naïve to androgen receptor inhibitors and in whom chemotherapy is not yet clinically indicated or appropriate where the following criteria have been met

Moved into routine commissioning - section B of list

Cetuximab in combination with fluoropyrimidine-based chemotherapy (CET5)

For chemotherapy-naive metastatic or locally advanced and inoperable colorectal cancer where all the following criteria are met:

Added to section B, merging forms CET1, CET2 and CET4

Panitumumab in combination with fluoropyrimidine-based chemotherapy (PAN4)

For chemotherapy-naive metastatic or locally advanced and inoperable colorectal cancer where the following criteria are met: Panobinostat for treating multiple

Added to section B, merging forms PAN1, PAN2 and PAN3

NHS England updates CDF List

Thu, 07 May 2026 23:00:00 GMT

NHS England updates CDF List

NHS England has updated the Cancer Drugs Fund List. The latest version (v1.395) was uploaded to the NHS England Website on Thursday 7, May 2026.

The following changes have been introduced:

Osimertinib monotherapy (OSI5)

For treating EGFR mutation positive unresectable locally advanced non-small- cell lung cancer after platinum-based chemoradiotherapy where the following criteria have been met

Recommended for routine commissioning, receiving CDF interim funding

Pembrolizumab (PEMB35)

Neo-adjuvant followed by adjuvant pembrolizumab for stage III macroscopic resectable melanoma in people 12 years and over where the following criteria have been met

Recommended for routine commissioning (NHS England clinical commissioning policy), added to section B

Belantamab mafodotin in combination with bortezomib and dexamethasone (BELA1)

Belantamab mafodotin in combination with bortezomib and dexamethasone as 2nd line treatment of relapsed or refractory myeloma in adult patients where the following criteria have been met

Date moving into routine commissioning updated; Treatment criterion (#1 and 4) updated; Treatment criterion (#11, 12, 13, 14 and 15) removed

Encorafenib in combination with binimetinib (ENC3)

For the first line treatment of metastatic BRAF V600 mutation positive non-small cell lung cancer where the following criteria have been met

Date moving into routine commissioning updated

Ripretinib (RIP1)

Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors where the following criteria have been met

Date moving into routine commissioning updated

Vorasidenib (VOR1)

For treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in patients aged 12 years and over where the following criteria have been met

Date moving into routine commissioning updated

Zanidatamab (ZANI1)

For the treatment of HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment where the following criteria have been met

Date moving into routine commissioning updated; Treatment criterion (#2, 3 and 5) updated

NA (BOS1)

Removed from section B

NA (CABA1)

Removed from section B

NA (DAS6)

Removed from section B

NA (ERIB1)

Removed from section B

NA (EVE1)

Removed from section B

NA (EVE5)

Removed from section B

NA (EVE6)

Removed from section B

NA (EVE7)

Removed from section B

NA (SOR2)

Removed from section B

NA (SOR3)

Removed from section B

NA (SOR5)

Removed from section B

Belantamab mafodotin with pomalidomide and dexamethasone (BELA2)

Treatment criteria (#1) updated; Treatment criterion (#12, 13, 14, 15 and 16) removed

Nivolumab (NIV25)

Nivolumab plus chemotherapy for neoadjuvant treatment and then continued as adjuvant monotherapy in adults with previously untreated UICC/AJCC 8th edition stage IIA or IIB or IIIA or N2 only IIIB non- small cell lung cancer AND who are candidates for potentially curative surgery where the following criteria have been met

Treatment criteria (#6) updated

Pembrolizumab (PEMB17)

Pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma in patients aged 3 years and older who have NOT been previously treated with stem cell transplantation brentuximab vedotin

Treatment criterion (#1, 11, 13 and 14) updated; Treatment criterion (#2 and 14) removed

Pembrolizumab (PEMB34)

Treatment criterion (#7 and 8) updated

NA (TEC1)

‘Drug’ column updated; Treatment criterion (#1, 9 and 15) updated; Treatment criterion (#14, 15, 16, 17, 18, 19, 20, 21 and 23) removed

Amivantamab in combination with lazertinib (AMI1)

Correction of ‘Date baseline funding started’

NHS England updates CDF List

Thu, 07 May 2026 23:00:00 GMT

NHS England updates CDF List

NHS England has updated the Cancer Drugs Fund List. The latest version (v1.396) was uploaded to the NHS England Website on Friday 8, May 2026.

The following changes have been introduced:

Amivantamab with carboplatin and pemetrexed (AMI2)

Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced, non- squamous, non-small-cell lung cancer where the following criteria have been met

Recommended for the CDF

NHS England updates CDF List

Mon, 20 Apr 2026 23:00:00 GMT

NHS England updates CDF List

NHS England has updated the Cancer Drugs Fund List. The latest version (v1.394) was uploaded to the NHS England Website on Tuesday 21, April 2026.

The following changes have been introduced:

Encorafenib in combination with binimetinib (ENC3)

For the first line treatment of metastatic BRAF V600 mutation positive non-small cell lung cancer where the following criteria have been met

Recommended for routine commissioning, receiving CDF interim funding

Zanidatamab (ZANI1)

For the treatment of HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment where the following criteria have been met

Recommended for routine commissioning, receiving CDF interim funding

Amivantamab in combination with lazertinib (AMI1)

Moved into routine commissioning - section B of list

Blinatumomab (BLI3)

The treatment of patients in first complete haematological complete remission and with minimal residual disease post 1st line induction chemotherapy in B-precursor acute lymphoblastic leukaemia in ADULT patients where all the following criteria are met:

Treatment criterion (#11) updated

Blinatumomab (BLI4)

The treatment of patients in first complete haematological remission and with minimal residual disease post 1st line induction chemotherapy in B-precursor acute lymphoblastic leukaemia in CHILD patients where all the following criteria have been met:

Treatment criterion (#12) updated

Blinatumomab (BLI5)

The treatment of ADULT patients in first morphological complete remission and without minimal residual disease after line intensive induction and intensification chemotherapy for Philadelphia chromosome negative B-cell precursor acute lymphoblastic leukaemiawhere all the following criteria are met:

Treatment criteria (#4 and 10) updated

Blinatumomab (BLI6)

The treatment of POST PUBESCENT CHILDREN in first morphological complete remission and without minimal residual disease after 1st line intensive induction and any indicated intensification chemotherapy for Philadelphia chromosome negative B-cell precursor acute lymphoblastic leukaemia where the following criteria have been met

Treatment criterion (#4) updated

Dabrafenib in combination with trametinib (DABTRA3)

For the first line treatment of metastatic BRAF V600 mutation positive non-small cell lung cancer where the following criteria have been met

Treatment criteria (#1, 5 and 10 updated)

Pembrolizumab (PEMB5)

The treatment of relapsed or refractory classical Hodgkin lymphoma in ADULTS who are stem cell transplant-ineligible and have failed brentuximab vedotin where the following criteria have been met

Treatment criteria (#8, 9 and 12) updated

Pembrolizumab monotherapy (PEMB25)

For the treatment of patients with ENDOMETRIAL carcinoma exhibiting microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) and who have progressive disease during or following prior platinum-containing therapy given in any setting for advanced or recurrent or metastatic disease and who are not candidates for potentially curative surgery or radiotherapy or chemoradiotherapy where the following criteria have been met

Treatment criteria (#1, 8, 10 and 12) updated

Venetoclax in combination with azacitidine (VEN8)

For untreated adult acute myeloid leukaemia in patients unsuitable for intensive chemotherapy where the following criteria have been met

Treatment criteria (#5 and 11) updated

Pembrolizumab (PEMB34)

Date moving into routine commissioning updated

NHS England updates CDF List

Wed, 01 Apr 2026 23:00:00 GMT

NHS England updates CDF List

NHS England has updated the Cancer Drugs Fund List. The latest version (v1.392) was uploaded to the NHS England Website on Wednesday 1, April 2026.

The following changes have been introduced:

Ripretinib (RIP1)

Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors where the following criteria have been met

Recommended for routine commissioning, receiving CDF interim funding

Vorasidenib (VOR1)

For treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in patients aged 12 years and over where the following criteria have been met

Recommended for routine commissioning, receiving CDF interim funding

Belantamab mafodotin with pomalidomide and dexamethasone (BELA2)

Correction - Moved into section A of list; Date moving into routine commissioning updated

Niraparib (NIR3) ## Niraparib (NIR3)

Niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy AND who HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation [NICE TA673] where the following criteria have been met There is a separate form NIR4 for use of niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy and who DO NOT HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation Niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy AND who HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation (TA673) where the following criteria have been met There is a separate form NIR4 for use of niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy and who DO NOT HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation

Correction - Moved into section A of list; Date moving into routine commissioning updated Correction - Moved into section A of list; Date moving into routine commissioning updated

Niraparib (NIR3) ## Niraparib (NIR3)

Correction - Moved into section A of list; Date moving into routine commissioning updated Correction - Moved into section A of list; Date moving into routine commissioning updated

Talazoparib plus enzalutamide (TAL2)

Correction - Moved into section A of list; Date moving into routine commissioning updated

NA (VEN7)

Removed from section A

Venetoclax in combination with obinutuzumab (VEN6)

For the treatment of patients with previously untreated chronic lymphatic leukaemia which doesn’t have a 17p deletion or TP53 mutation where the following criteria have been met

Indication column updated; Several treatment criterion updated; combined with previous VEN7 form

Epcoritamab monotherapy (EPC2)

Epcoritamab monotherapy for previously treated adult patients with relapsed/refractory follicular lymphoma who have received 2 or more lines of systemic therapy where the following criteria have been met

Correction of Date moving into routine commissioning

NHS England updates CDF List

Thu, 26 Mar 2026 00:00:00 GMT

NHS England updates CDF List

NHS England has updated the Cancer Drugs Fund List. The latest version (v1.391) was uploaded to the NHS England Website on Thursday 26, March 2026.

The following changes have been introduced:

Pembrolizumab (PEMB34)

Correction of ‘Available to new patients’

NHS England updates CDF List

Wed, 25 Mar 2026 00:00:00 GMT

NHS England updates CDF List

NHS England has updated the Cancer Drugs Fund List. The latest version (v1.390) was uploaded to the NHS England Website on Tuesday 24, March 2026.

The following changes have been introduced:

Pembrolizumab (PEMB34)

Recommended for routine commissioning, receiving CDF interim funding

Belantamab mafodotin with pomalidomide and dexamethasone (BELA2)

Moved into routine commissioning - section B of list

NA (DOS3)

Moved into routine commissioning - section B of list

Niraparib (NIR3)

Moved into routine commissioning - section B of list

Obecabtagene autoleucel (OBE01a)

Obecabtagene autoleucel (obecel) CAR-T cells for treating relapsed/refractory Philadelphia negative or positive B cell precursor acute lymphoblastic leukaemia in patients aged 26 years and older where the following criteria have been met This form is for the approval of leucapheresis and manufacture of CAR-T cells. There is a second part to this form which relates to the subsequent infusion of CAR-T cells and this will be available after submission of the first part. The second part of the form (OBE01b) can only be completed as a continuation of this first part of the form (OBE01a) and OBE01b must be completed on infusion CAR-T cells otherwise the treating Trust will not be reimbursed for the cost of obecabtagene autoleucel (obecel). Note: the second part of the form (OBE01b) will only appear after the above first part of the form (OBE01a) has been fully completed and submitted. To complete the second part of the form, the user will have to complete a continuation request for the OBE1a application.

Moved into routine commissioning - section B of list

Talazoparib plus enzalutamide (TAL2)

Moved into routine commissioning - section B of list

Epcoritamab monotherapy (EPC2)

Date moving into routine commissioning updated

Lenvatinib with everolimus (LNV1)

The treatment of previously treated advanced renal cell carcinoma

Treatment criterion (#10 and 11) updated; Treatment criteria (#10) removed

Trastuzumab emtansine MONOTHERAPY (TRA2)

As adjuvant therapy for patients with HER2-positive early breast cancer who have residual invasive disease following the combination of taxane-based and HER2-targeted neoadjuvant systemic therapy and surgery where the following criteria have been met

Drug column updated; Treatment criterion (#5 and 10) updated; Treatment criterion (#7 and 11) removed

NHS England updates CDF List

Fri, 20 Mar 2026 00:00:00 GMT

NHS England updates CDF List

NHS England has updated the Cancer Drugs Fund List. The latest version (v1.389) was uploaded to the NHS England Website on Sunday 22, March 2026.

The following changes have been introduced:

Nivolumab (NIV25)

Correction of Nice Approved Indication

NHS England updates CDF List

Tue, 10 Mar 2026 00:00:00 GMT

NHS England updates CDF List

NHS England has updated the Cancer Drugs Fund List. The latest version (v1.388) was uploaded to the NHS England Website on Monday 9, March 2026.

The following changes have been introduced:

Glofitamab in combinaton with gemcitabine and oxaliplatin (GLO2)

Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B- cell lymphoma where the following criteria have been met

Moved into routine commissioning - section B of list

Talquetamab monotherapy (TALQ1)

For treating relapsed or refractory multiple myeloma after 3 or more treatments where the following criteria have been met

Moved into routine commissioning - section B of list

Nivolumab (NIV25) ## Nivolumab (NIV25)

Nivolumab plus ipilimumab for previously untreated patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic or locally advanced and inoperable colorectal cancer where the following criteria have been met Nivolumab plus ipilimumab for previously untreated patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic or locally advanced and inoperable colorectal cancer where the following criteria have been met

Moved into routine commissioning - section B of list; Treatment criteria (#9) updated Treatment criteria (#9) updated

Durvalumab with gemcitabine and cisplatin (DUR8)

For neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer where the following criteria have been met

Date moving into routine commissioning updated

Bevacizumab with FIRST LINE fluoropyrimidine-based chemotherapy (BEV11)

For metastatic or locally advanced and inoperable colorectal cancer where the following criteria have been met

‘TA’ and ‘Date of Final NICE Guidance’ columns updated

Nivolumab (NIV25) ## Nivolumab (NIV25)

Moved into routine commissioning - section B of list; Treatment criteria (#9) updated Treatment criteria (#9) updated

Pembrolizumab (PEMB9a)

Treatment criteria (#9) updated

Pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy (PEMB15)

For previously untreated advanced oesophageal carcinoma which expresses PD-L1 with a combined positive score of 10 or more where the following criteria have been met

Treatment criterion (#9, 10 and 12) updated; Treatment criterion (#2 and 13) removed

Pembrolizumab in combination with lenvatinib (PEMB23)

For the treatment of patients with endometrial carcinoma who have progressive disease during or following prior platinum-containing therapy given any setting for advanced or recurrent or metastatic disease and who are not candidates for potentially curative surgery or radiotherapy or chemoradiotherapy where the following criteria have been met

Treatment criterion (#8, 9, 10, 11, 13 and 15) updated; Treatment criterion (#2, 10 and 17) removed

NHS England updates CDF List

Tue, 24 Feb 2026 00:00:00 GMT

NHS England updates CDF List

NHS England has updated the Cancer Drugs Fund List. The latest version (v1.387) was uploaded to the NHS England Website on Monday 23, February 2026.

The following changes have been introduced:

Epcoritamab monotherapy (EPC2)

Recommended for routine commissioning, receiving CDF interim funding

Carfilzomib in combination with lenalidomide and dexamethasone (CAR2)

For the treatment of previously treated multiple myeloma in patients who have had 1 prior line of systemic therapy where the following criteria have been met

Treatment criterion (#6 and 13) updated; Treatment criteria (#13) removed

Pembrolizumab (PEMB7)

Pembrolizumab for adjuvant treatment melanoma with high risk of recurrence where the following criteria have been met

Treatment criteria (#10) updated; Treatment criterion (#2 and 11) removed

Pembrolizumab (PEMB8)

Treatment criteria (#13) updated; Treatment criterion (#2 and 14) removed

Pembrolizumab (PEMB12)

For previously untreated metastatic or unresectable recurrent PD-L1 positive head and neck squamous cell carcinoma (HNSCC) where the following criteria have been met

Treatment criterion (#6, 7 and 10) updated; Treatment criteria (#2) removed

Pembrolizumab (PEMB14)

For the 1st line treatment of patients with either metastatic or locally advanced and inoperable colorectal cancer exhibiting microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR) where the following criteria have been met

Treatment criterion (#10 and 12) updated; Treatment criterion (#2, 13 and 15) removed

Pembrolizumab (PEMB19)

Pembrolizumab monotherapy for adjuvant treatment after complete tumour resection of renal cell carcinoma in adult patients at increased risk of recurrence following nephrectomy or following nephrectomy and resection of all metastatic disease where the following criteria have been met

Treatment criterion (#8, 10 and 11) updated; Treatment criterion (#2, 11 and 13) removed

Pembrolizumab (PEMB20)

Pembrolizumab for the adjuvant treatment of newly diagnosed and completely resected stage IIB or stage IIC malignant melanoma where the following criteria have been met

Treatment criteria (#10) updated; Treatment criterion (#2 and 11) removed

Pembrolizumab (PEMB21)

Pembrolizumab in combination with chemotherapy as neoadjuvant treatment and then continued as adjuvant monotherapy after definitive surgery for patients with previously untreated locally advanced or early stage triple negative breast cancer at high risk of recurrence where the following criteria have been met

Treatment criterion (#10, 13, 15 and 17) updated; Treatment criterion (#2 and 18) removed

Pembrolizumab in combination with chemotherapy with or without bevacizumab (PEMB22)

For the treatment of persistent, recurrent or metastatic cervical cancer in patients whose tumour PD-L1 expression test results have a combined positive score (CPS) of 1 or more where the following criteria have been met

Treatment criterion (#10, 11, 15 and 16) updated; Treatment criterion (#2 and 16) removed

Pembrolizumab in combination with chemotherapy (PEMB30)

Pembrolizumab in combination with chemotherapy for neoadjuvant treatment and then continued as adjuvant monotherapy in adults with previously untreated UICC/AJCC 8th edition stage IIA or IIB or IIIA or N2 only IIIB non-small cell lung cancer AND who are candidates for potentially curative surgery where the following criteria have been met

Treatment criteria (#9) updated